Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S‐1 as second‐line chemotherapy in metastatic pancreatic cancer

Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S‐1 as second‐line chemotherapy in metastatic pancreatic cancer

Abstract Background and Aim The optimal standard second‐line chemotherapy for metastatic pancreatic cancer (MPC) remains unclear. Here, we evaluated the efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with oral fluoropyrimidine S‐1 as a...

Full description

Bibliographic Details
Main Authors: Kenji Ikezawa, Ryosuke Kiyota, Ryoji Takada, Kazuma Daiku, Shingo Maeda, Toshihiro Imai, Yutaro Abe, Yugo Kai, Takuo Yamai, Nobuyasu Fukutake, Tasuku Nakabori, Reiko Ashida, Hiroyuki Uehara, Takahiro Tabuchi, Kazuhiro Katayama, Kazuyoshi Ohkawa
Format: Article
Language:English
Published: Wiley 2021-06-01
Series:JGH Open
Subjects:
adverse event
overall survival
pancreatic adenocarcinoma
peripheral sensory neuropathy
progression‐free survival
Online Access:https://doi.org/10.1002/jgh3.12555

Internet

https://doi.org/10.1002/jgh3.12555

Similar Items